ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0505

Risk of Venous and Arterial Thromboembolism in Patients with Giant Cell Arteritis And/or Polymyalgia Rheumatica: A Veterans Health Administration Population-Based Study in the United States

Despina Michailidou1, Tianyu Zhang2, Pavlos Stamatis3 and Bernard Ng4, 1Division of Rheumatology, University of Washington, Seattle, WA, 2Department of Biostatistics, University of Washington, Seattle, WA, 3Lund University, Lund, Sweden, 4Rheumatology Section, VA Puget Sound HCS, University of Washington, Seattle, WA

Meeting: ACR Convergence 2021

Keywords: Central retinal vascular occlusive events, Deep venous thrombosis, giant cell arteritis, Polymyalgia Rheumatica (PMR), pulmonary

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 6, 2021

Title: Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders (0502–0507)

Session Type: Abstract Session

Session Time: 4:15PM-4:30PM

Background/Purpose: Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are two chronic systemic inflammatory diseases that primarily affect elderly women. Both diseases can be complicated by inflammatory induced thrombosis, however the risk of thromboembolism among male patients with GCA and/or PMR is yet unknown. Due to the tight relationship between inflammation and thrombosis contributing to increased morbidity and mortality, we sought to determine the incidence rate of venous and arterial thrombotic events in patients with GCA and/or PMR among Veterans of the US. The objective of this study was to evaluate the risk of thromboembolism and retinal vascular events in GCA, PMR, and/or overlap of GCA with PMR compared to osteoarthritis (OA) in a Veteran’s based population.

Methods: 1,581 patients with GCA, 10,940 with PMR, and 1,230 with GCA and PMR as well as 120,708 age- and sex-matched patients with OA, were identified in this retrospective study. Incidence rate ratios (IRR) of pulmonary embolism (PE), deep venous thrombosis (DVT), arterial thromboembolism of extremities (ATE), central retinal artery and vein occlusion (CRAO and CRVO) were calculated. We also calculated hazard ratios (HRs) of thromboembolic events in study groups, adjusting for independent risk factors of thromboembolism.

Results: Patients with GCA, PMR and GCA with PMR had higher IRs of all thromboembolic events as compared to patients with OA (Table 1). Patients with overlap of GCA and PMR had a lower risk of deep venous thrombosis (HR: 2.13, 95%CI:1.53-2.97, p< 0.001) and retinal vascular events (HR: 4.46, 95%CI:2.49-7.96, p< 0.001) as compared to patients with GCA (HR: 4.17, 95%CI:3.38-5.15, p< 0.001, and HR: 10.60, 95%CI: 7.56-14.86, p< 0.001, respectively), but a higher risk of retinal vascular events as compared to patients with PMR (HR: 2.33, 95%CI:1.75-3.11, p< 0.001) (Table 2).

Conclusion: The risk of thromboembolic events was higher in patients with GCA, PMR, and GCA with PMR compared to referenced population, and differed based on disease diagnosis. These findings may alert providers to be mindful of the importance for close monitoring of these patients for thromboembolic risk factors and may emphasize the need for a risk stratification strategy that would allow identification of high-risk patients.


Disclosures: D. Michailidou, None; T. Zhang, None; P. Stamatis, None; B. Ng, None.

To cite this abstract in AMA style:

Michailidou D, Zhang T, Stamatis P, Ng B. Risk of Venous and Arterial Thromboembolism in Patients with Giant Cell Arteritis And/or Polymyalgia Rheumatica: A Veterans Health Administration Population-Based Study in the United States [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/risk-of-venous-and-arterial-thromboembolism-in-patients-with-giant-cell-arteritis-and-or-polymyalgia-rheumatica-a-veterans-health-administration-population-based-study-in-the-united-states/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/risk-of-venous-and-arterial-thromboembolism-in-patients-with-giant-cell-arteritis-and-or-polymyalgia-rheumatica-a-veterans-health-administration-population-based-study-in-the-united-states/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology